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Summary -3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), have beneﬁcial effects on cardiovascular diseases. Cytochrome
P-450 (CYP) 2J2 that is expressed in endothelial cells metabolizes arachidonic
acids to biologically active epoxyeicosatrienoic acids (EETs) that possess anti-
inﬂammatory and anti-thrombotic effects.
We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by
reverse transcription-polymerase chain reaction in cultured human umbilical vein
endothelial cells and found that EPA, but not DHA, increased the expression of
se-dependent and a time-dependent manner. EPA-inducedCYP 2J2 mRNA in a do
CYP 2J2 expression was signiﬁcantly inhibited by pretreatment with a peroxisome
proliferator-activated receptor (PPAR)  antagonist, GW9662. EPA, but not DHA,
caused a signiﬁcant increase in cellular levels of 11,12-dihydroxyeicosatrienoic acid
that is a stable metabolite of 11,12-EET, which was blocked by pretreatment with
GW9662.
∗ Corresponding author. Tel.: +81 952 34 2364; fax: +81 952 34 2089.
E-mail address: hiraset@med.saga-u.ac.jp (T. Hirase).
0914-5087/$ — see front matter © 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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These data demonstrate that EPA increases CYP 2J2 mRNA expression and 11,12-EET
production via PPAR in endothelial cells and indicate a novel protective role of EPA
and PPAR against vascular inﬂammation.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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ntroduction
ccumulating evidence has revealed that -3
atty acids, such as eicosapentaenoic acid (EPA)
nd docosahexaenoic acid (DHA), have beneﬁcial
ffects, including lipid lowering, blood pressure
owering and anti-arrhythmic effects, on cardio-
ascular diseases [1,2]. EPA and DHA exert their
iological effects by activating cell signaling path-
ays. It has been demonstrated that EPA increases
he activity of peroxisome proliferator-activated
eceptor  (PPAR) [3]. PPAR, a member of the
teroid/retinoid nuclear receptor family of ligand-
ctivated transcription factors, is expressed in
ascular cells and inﬂammatory cells [4]. The acti-
ation of PPAR appears to have anti-atherogenic
ffects through the inhibition of endothelial adhe-
ion molecule expression, proliferation of vascular
mooth muscle cells, and modiﬁed low-density
ipoprotein receptor expression in macrophages
5—7].
Cytochrome P-450 (CYP) 2J2 that is expressed
n vascular endothelial and smooth muscle cells
nd cardiomyocytes metabolizes arachidonic acid
o biologically active epoxyeicosatrienoic acids
EETs) [8]. 11,12-EET produced by CYP 2J2 has
nti-inﬂammatory properties such as prevention of
eukocyte adhesion to endothelial cells by inhibit-
ng nuclear factor-B that stimulates the expression
f proinﬂammatory gene products in endothe-
ial cells [8]. 5,6-, 8,9-, 11,12-, and 14,15-EETs
ave vasodilatory effects by polarization and relax-
tion of vascular smooth muscle cells. EETs also
re reported to have anti-thrombotic effects by
pregulating tissue plasminogen activator and anti-
igratory effects against vascular smooth muscle
ells through decreasing the production of reactive
xygen species [9]. Spiecker et al. demonstrated
hat a polymorphism of the CYP 2J2 gene that
esults in decreased CYP 2J2 promoter activity and
ower plasma concentrations of EET metabolites is
ndependently associated with an increased risk of
oronary artery disease [10]. Thus, it is suggested
hat CYP 2J2-induced EETs have protective effects
gainst atherosclerosis and vascular remodeling.
In this study, we investigated the effects of
PA and DHA on the expression of CYP 2J2 mRNA
y reverse transcription-polymerase chain reaction
t
2
C
n
RRT-PCR) in cultured human umbilical vein endothe-
ial cells (HUVECs). EETs that are produced from
rachidonic acids by 2C and 2J classes of CYP
poxygenases are quickly metabolized into stable
etabolites, dihydroxyeicosatrienoic acids (DHETs)
8,10]. Therefore, cellular DHET levels are consid-
red to be a surrogate marker of cellular EET levels.
o investigate the effects of EPA and DHA on the
poxygenase activity to produce EET in endothe-
ial cells, we studied the effects of EPA and DHA on
ellular levels of 11,12-DHET in HUVECs by enzyme-
inked immunoassay (ELISA). Also, the involvement
f PPAR in the signaling pathway that induces
YP 2J2 gene expression and 11,12-EET production
n HUVECs was studied using a PPAR antagonist,
W9662.
ethods
aterials
PA and DHA were purchased from Sigma (St Louis,
O, USA). GW9662 was obtained from Cayman
hemical Co. (Ann Arbor, MI, USA).
ell culture
UVECs purchased from Cambrex (Walkersville,
D, USA) were cultured in RPMI medium (Sigma)
ontaining 20% fetal bovine serum, 25 units/ml hep-
rin, 20mg/ml endothelial cell growth supplement,
00U/ml penicillin, and 100g/ml streptomycin.
everse transcription-polymerase chain
eaction
otal RNA was isolated from cells with Iso-
en (Nippon Gene, Toyama, Japan) following the
anufacturer’s protocol. cDNA synthesis was per-urer’s protocol. The speciﬁc primer sets for CYP
J2 were 5′-GGACTCTCCTACTGGGCACT-3′ and 5′-
TCCGAAGGTGATGGAGCAA-3′ (Genbank accession
o. U37143). -Actin was ampliﬁed using Quantum
NA -actin Internal Standards from Ambion.
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After an initial denaturation step at 94 ◦C for
5min, the reactions underwent 27 cycles of 1min
at 94 ◦C, 2min at 65 ◦C, and 3min at 72 ◦C.
PCR products were electrophoresed on 2% agarose
gels followed by ethidium bromide staining. The
mRNA expression levels were normalized by -actin
expression and presented as the relative expression
level compared to that of control cells.
DHET measurement
HUVECs that were treated with EPA or control
vehicle for 24 h in the presence or absence of
GW9662 were scraped into tubes. Cells were
sonicated in phosphate buffered saline contain-
ing triphenylphosphine. After pH adjustment with
acetic acid, homogenized cells were extracted
with ethyl acetate. After centrifugation, organic
phase was evaporated, reconstituted with N,N-
dimethyl formamide, and was subjected to ELISA
assay. Commercially available ELISA kit to measure
11,12-DHET (Detroit R&D, Inc., MI, USA) was used
following the manufacturer’s protocol.Statistical analysis
Data from ﬁve independent experiments are shown
as means± S.E. Statistical signiﬁcance, calculated
e
m
T
s
Figure 1 Eicosapentaenoic acid (EPA) induces cytochrome
manner. Total RNA extracted from human umbilical vein endo
hexaenoic acid (DHA) (B) at indicated dose for 24 h was subje
(RT-PCR) analysis for CYP 2J2 mRNA expression. The PCR p
(upper panels). The band intensity of CYP 2J2 was adjusted
the mean± S.E. of ﬁve independent experiments expressed a
cells (lower panels). *p < 0.05 vs. untreated control.D. Wang et al.
sing Mann—Whitney’s U test and Wilcoxson signed-
ank test, was taken as p < 0.05.
esults
PA stimulates CYP 2J2 mRNA expression in
ndothelial cells in a dose-dependent
anner
e investigated the effects of EPA and DHA on
he expression of CYP 2J2 mRNA in endothelial
ells by RT-PCR. HUVECs were treated with control
ehicle, EPA, and DHA at indicated dose for 24 h.
s shown in Fig. 1A, 10−6 and 10−5 M of EPA
igniﬁcantly increased CYP 2J2 mRNA expression in
dose-dependent manner. In contrast, DHA had no
igniﬁcant effects on CYP 2J2 mRNA expression in
he same dose range (Fig. 1B). These data indicate
hat EPA, but not DHA, stimulates CYP 2J2 mRNA
xpression in endothelial cells in a dose-dependent
anner.
PA stimulates CYP 2J2 mRNA expression in
ndothelial cells in a time-dependent
anner
o study the time course of CYP 2J2 mRNA expres-
ion induced by EPA in endothelial cells, HUVECs
P-450 (CYP) 2J2 mRNA expression in a dose-dependent
thelial cells that were treated with EPA (A) and docosa-
cted to reverse transcription-polymerase chain reaction
roducts were analyzed by agarose gel electrophoresis
with the band intensity of -actin, and data shown are
s the fold increase compared with the value for control
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Figure 2 Eicosapentaenoic acid (EPA) induces cytochrome P-450 (CYP) 2J2 mRNA expression in a time-dependent
manner. Total RNA extracted from human umbilical vein endothelial cells that were treated with 10−5 M of EPA (A)
and docosahexaenoic acid (DHA) (B) for the indicated time was subjected to reverse transcription-polymerase chain
reaction (RT-PCR) analysis for CYP 2J2 mRNA expression. The PCR products were analyzed by agarose gel electrophoresis
(upper panels). The band intensity of CYP 2J2 was adjusted with the band intensity of -actin, and data shown are
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Fhe mean± S.E. of ﬁve independent experiments express
ells (lower panels). *p < 0.05 vs. untreated control.
ere treated with 10−5 M of EPA for the indicated
ime. As shown in Fig. 2A, treatment with EPA for
2 and 24 h signiﬁcantly increased CYP 2J2 mRNA
xpression compared to basal expression of CYP
J2 mRNA in HUVECs. In contrast, DHA treatment
howed no signiﬁcant effects on CYP 2J2 mRNA
xpression in HUVECs (Fig. 2B). These data indicate
hat EPA, but not DHA, stimulates CYP 2J2 mRNA
xpression in endothelial cells in a time-dependent
anner.
nvolvement of PPAR in CYP 2J2 mRNA
xpression in endothelial cells
t has been shown that EPA induces PPAR activation
hat results in gene expression [3]. To investigate
he involvement of PPAR in EPA-induced CYP 2J2
xpression in endothelial cells, HUVECs that were
retreated with a PPAR antagonist GW9662 or con-
rol vehicle were stimulated with EPA (10−5 M) for
4 h. As shown in Fig. 3, pretreatment with GW9662
igniﬁcantly prevented the EPA-induced upregu-
ation of CYP 2J2 mRNA expression in HUVECs.
retreatment with GW9662 had no obvious effects
n basal CYP 2J2 expression. These results indi-
ate that PPAR is involved in EPA-induced CYP 2J2
xpression in endothelial cells.
l
i
l
1s the fold increase compared with the value for control
PA stimulates EET production via PPAR in
ndothelial cells
he epoxygenase activity of CYP 2J2 and 2C9
s demonstrated to metabolize arachidonic acid
nto EETs including 11,12-EET and 14,15-EET that
ave vasodilatory and anti-inﬂammatory proper-
ies [8]. Among EETs, 11,12-EET is the most potent
iologically active metabolite. EETs are quickly
etabolized into a stable metabolite DHETs includ-
ng 11,12-DHET and 14,15-DHET. Therefore, cellular
HET levels are considered to be a surrogate marker
f cellular EET levels [8,10]. To study the effects of
PA and DHA on the CYP epoxygenase activity to
roduce 11,12-EET in endothelial cells, we mea-
ured cellular 11,12-DHET levels by ELISA. Also,
he involvement of PPAR was examined using a
harmacological PPAR antagonist GW9662. Cell
ysates prepared from HUVECs stimulated with con-
rol vehicle, EPA, or DHA at indicated dose after
retreatment with a PPAR antagonist GW9662 or
ontrol vehicle were subjected to ELISA assay to
easure cellular 11,12-DHET levels. As shown in
ig. 4, 10−5 M of EPA signiﬁcantly increased cellu-
ar 11,12-DHET levels up to 1.9± 0.3-fold of control
n HUVECs. DHA had no signiﬁcant effects on cel-
ular 11,12-DHET levels. An increase of cellular
1,12-DHET induced by EPA was abolished by pre-
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Figure 3 Involvement of peroxisome proliferator-
activated receptor (PPAR)  in eicosapentaenoic acid
(EPA)-induced cytochrome P-450 (CYP) 2J2 mRNA expres-
sion in endothelial cells. Total RNA extracted from human
umbilical vein endothelial cells that were pretreated with
a PPAR antagonist GW9662 (10−7 M) and then stimu-
lated with EPA (10−5 M) for 24 h was subjected to reverse
transcription-polymerase chain reaction (RT-PCR) analy-
sis for CYP 2J2 mRNA expression. The PCR products were
analyzed by agarose gel electrophoresis (upper panel).
The band intensity of CYP 2J2 was adjusted with the band
intensity of -actin, and data shown are the mean± S.E.
of ﬁve independent experiments expressed as the fold
Figure 4 Eicosapentaenoic acid (EPA) stimulates
epoxyeicosatrienoic acid (EET) production via per-
oxisome proliferator-activated receptor (PPAR)  in
endothelial cells. Cell lysates prepared from human
umbilical vein endothelial cells stimulated with EPA and
docosahexaenoic acid (DHA) at the indicated dose after
pretreatment with a PPAR antagonist GW9662 or control
vehicle were subjected to enzyme-linked immunoassay
to measure cellular 11,12-dihydroxyeicosatrienoic acid
(DHET) levels, as described in Methods. Data shown
are the mean± S.E. expressed as the fold increase
in cellular levels of 11,12-DHET in ﬁve independent
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aincrease compared with the value for control cells (lower
panel). * and # indicate p < 0.05 vs. untreated control and
EPA-treated cells, respectively.
treatment with GW9662. These data indicate that
EPA, but not DHA, increases 11,12-EET production
via PPAR in endothelial cells.
Discussion
The epoxygenases that synthesize EETs in endothe-
lial cells are primarily CYP 2C9 and CYP 2J2
[8,11,12]. As EETs produced by CYP 2J2 have
anti-inﬂammatory effects that are potentially vaso-
protective, we studied changes in the expression of
CYP 2J2 in cultured human endothelial cells and
found that EPA, but not DHA, increases CYP 2J2
gene expression. In accordance with the increase in
CYP 2J2 gene expression, cellular levels of 11,12-
DHET that is a stable metabolite of 11,12-EET were
increased in response to EPA in endothelial cells.
a
l
i
sxperiments compared with the value for control cells. *
nd # indicate p < 0.05 vs. untreated control and 10−5 M
PA-treated cells, respectively.
YP 2C that produces vasodilatory EETs is impli-
ated in the regulation of endothelial proliferation
nd angiogenesis [13,14]. So far, molecular mech-
nisms that are responsible for induction of CYP
J2 and CYP 2C are not fully understood. CYP 2J2
nd CYP 2C proteins rapidly and markedly decrease
n cell isolation for cell culture. To differentially
nactivate the isoforms of CYP 2J and CYP 2C have
ot been achieved. Future studies are necessary to
etermine the major source of EPA-induced EETs in
ndothelial cells. Our present study also provides
ovel ﬁndings that PPAR mediates EPA-induced
YP 2J2 expression. The results in the present
tudy indicate that EPA and DHA have differen-
ial effects on CYP 2J2 expression in endothelial
ells. Omura et al. demonstrated that EPA, but
ot DHA, activates endothelial nitric oxide synthase
nd increases nitric oxide production in endothe-
ial cells [15]. These data suggest that EPA and DHA
timulate differential signaling pathways probably
epending on cell types.
It is likely that the effects of EETs are medi-
ted by binding to postulated membrane receptors
s well as by interacting directly with intracellu-
ar signaling molecules, transcription factors, and
on channels [16]. 11,12-EET is shown to activate a
ignaling pathway mediated by Gs that is a compo-
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ent of a heterodimeric GTP-binding protein [9]. On
he other hand, EETs bind to intracellular proteins
hat contain fatty acid binding sites including PPAR
17]. Interestingly, Huang et al. demonstrated that
hear stress induces EPA-mediated EET production
n endothelial cells [18]. Therefore, there is a possi-
ility that 11,12-EET induced by EPA has additional
ffects on EPA-stimulated PPAR activity.
PPAR is reportedly expressed in endothelial
ells, vascular smooth muscle cells, and human
therosclerotic lesions [4,19]. Previous studies have
evealed anti-inﬂammatory effects of PPAR ago-
ists on endothelial cells such as inhibition of
he expression of adhesion molecules, increased
itric oxide bioavailability, and repression of NADPH
xidase activity [20,21]. Xu et al. reported the
inding of EPA to the ligand-binding domain of
PAR [22]. The structural homology among PPAR
soforms is divergent in the ligand-binding domain
nd the interaction between EPA and PPAR is not
et determined [23]. It is reported that PPAR
RNA expression was not changed by EPA treatment
n certain types of cells [24]. We also conﬁrmed
hat EPA did not signiﬁcantly change PPAR mRNA
xpression in HUVECs, suggesting that EPA increases
PAR activity without upregulation of its mRNA
data not shown). Although further studies are nec-
ssary to investigate a possibility that EPA binds to
PAR and mechanisms how EPA activates CYP 2J2
ranscription, our present study provides novel evi-
ence that EPA stimulates CYP 2J2 transcription via
PAR.
In summary, our data indicate that EPA-induced
YP 2J2 expression and EET production in endothe-
ial cells contribute to vasoprotective effects of
PA. Also, endothelial PPAR activity appears to be
equired for EPA to stimulate CYP 2J2 expression,
uggesting a possible therapeutic effect of a com-
ination of EPA and synthetic PPAR agonists for
ardiovascular diseases.
onclusion
he present study demonstrates that EPA, but not
HA, increases CYP 2J2 mRNA expression and 11,12-
ET production in endothelial cells via PPAR,
ndicating a novel vascular protective effect of EPA.
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